The Orexin 2 Receptor Agonist ALKS 2680 in Patients with Narcolepsy Type 1: An Initial Proof of Concept Phase 1b Study (P8-4.004)

Ron Grunstein; Brendon Yee; Julia Chapman; Angela D’rozario; Craig Hopkinson; Jandira Ramos; Daniel Smith; Sergey Yagoda; Bhaskar Rege

doi:10.1212/wnl.0000000000210498

Home
Search
The Orexin 2 Receptor Agonist ALKS 2680 in Patients with Narcolepsy Type 1: An Initial Proof of Concept Phase 1b Study (P8-4.004)

2
https://doi.org/10.1212/wnl.0000000000210498

The Orexin 2 Receptor Agonist ALKS 2680 in Patients with Narcolepsy Type 1: An Initial Proof of Concept Phase 1b Study (P8-4.004)

Apr 8, 2025
Neurology
Ron Grunstein +8 more

Listen

Abstract
Literature Map
Citations
Similar Papers

Abstract

To present the results from a randomized, double-blind, phase 1b study assessing the safety, tolerability, and pharmacodynamics of ALKS 2680 in patients with narcolepsy type 1 (NT1).